论文部分内容阅读
为了深入观察峰龄胶囊在化疗中的作用，将需常规化疗的78例肺癌患者随机分成化疗前2周给药的治疗A组、化疗前1周给药的治疗B组和不给药的对照组，肺癌的化疗用MVP方案（非小细胞型）和CAV（或CE）方案（小细胞型），采用常规剂量。结果发现：对照组、治疗B组、治疗A组白细胞、血小板的下降程度在化疗后1周尚无显著差异，而在化疗后2周则依次减轻，血红蛋白下降程度在化疗后1周和2周均无显著差异；发生恶心、呕吐的比例和程度在化疗后3天亦依次下降，在化疗后1周则无差异，但食欲改善所需天数明显减少；肝功能损害发生率依次下降，白／球蛋白比值升高则依次增加，提示峰龄胶囊在化疗前给药可以提高机体对化疗的耐受性，保护骨髓的造血功能，减轻毒副反应，有利于常规化疗按时进行，而且提前2周给药明显优于1周给药。
To deeply observe the role of Fengling capsule in chemotherapy, 78 patients with lung cancer undergoing conventional chemotherapy were randomly divided into treatment group A given 2 weeks prior to chemotherapy, treatment group B given 1 week before chemotherapy, and non-administered control Groups, chemotherapy for lung cancer use the MVP regimen (non-small cell type) and the CAV (or CE) regimen (small cell type) with conventional doses. The results showed that there was no significant difference in the decrease of white blood cells and platelets in the control group, the treatment group B, and the treatment group A at 1 week after chemotherapy, but decreased at 2 weeks after chemotherapy. The degree of hemoglobin decline was 1 week and 2 weeks after chemotherapy. There was no significant difference; the proportion and degree of nausea and vomiting also decreased in turn after 3 days of chemotherapy. There was no difference in 1 week after chemotherapy, but the number of days required for improvement of appetite decreased significantly; the incidence of liver damage decreased in turn. The globulin ratio increased sequentially, suggesting that administration of Fengling Capsule before chemotherapy can improve the body’s tolerance to chemotherapy, protect hematopoietic function of the bone marrow, reduce toxic side effects, and facilitate conventional chemotherapy to be performed on time, and 2 weeks in advance. Administration was significantly better than one week administration.